Lupin Limited has successfully appointed Mr. Anand Kripalu as an Independent Director following the completion of its postal ballot process on February 13, 2026. The pharmaceutical company announced that the special resolution for his appointment received requisite majority approval from shareholders, with the appointment now officially disclosed under Regulation 30 of SEBI listing requirements.

Postal Ballot Results Overview

The postal ballot process demonstrated strong shareholder participation and support for the appointment. The voting results showed comprehensive engagement across all shareholder categories.

Category-wise Voting Pattern

The voting pattern revealed unanimous support from promoters and strong backing from institutional investors. Promoter and Promoter Group shareholders, holding 214,212,684 shares, voted with 100.00% participation and complete support for the resolution.

Leadership Experience and Background

Anand Kripalu brings over three decades of leadership experience in the fast-moving consumer goods (FMCG) sector to Lupin's board. He currently serves as Executive Director of EPL Limited and previously served as its Managing Director and Global CEO until December 31, 2025.

Kripalu graduated from IIT Madras with a B.Tech in Electronics and earned an MBA from IIM Calcutta. He is a recipient of the Distinguished Alumnus Award from both institutions and has completed the Advanced Management Program at Wharton Business School.

Current Board Positions and Strategic Value

Kripalu currently serves as an Independent Director on the boards of Swiggy Limited and United Breweries Limited, having previously served as a director at Marico Limited. His extensive experience across consumer goods, technology, and beverage sectors provides valuable cross-industry insights.

Manju D Gupta, Chairman of Lupin, commented on the appointment: "We are delighted to welcome Anand to the Board. His vast experience will be invaluable in advancing Lupin's strategic priorities and reinforcing our position in the global pharmaceutical industry."

Process and Timeline

The postal ballot process was conducted entirely through remote e-voting, following regulatory guidelines and MCA circulars. The company appointed National Securities Depository Limited (NSDL) as the e-voting service provider, with Saurabh Agarwal serving as the appointed Scrutinizer.

The appointment strengthens Lupin's board composition with independent directorship expertise and cross-sector leadership experience, supporting the company's strategic initiatives in the global pharmaceutical market.

Lupin Limited has announced the allotment of 75,273 equity shares under its Employee Stock Option Plan (ESOP) on February 13, 2026. The pharmaceutical company informed stock exchanges about this development through a regulatory filing pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Share Allotment Details

The Operations and Finance Committee of Lupin approved the allotment during its meeting held on February 13, 2026. The allotted shares represent fully paid-up equity shares with a face value of ₹2 each.

Impact on Share Capital

Following the ESOP allotment, Lupin's capital structure has been updated to reflect the increased share count. The allotment was made upon exercising of vested options granted to employees under the company's stock option plans.

Regulatory Compliance

The company has duly informed both the National Stock Exchange of India Limited and BSE Limited about the share allotment. The disclosure was signed by Amit Kumar Gupta, Company Secretary and Compliance Officer, ensuring compliance with regulatory requirements for listed companies.

This ESOP allotment reflects Lupin's ongoing commitment to employee participation in the company's growth through equity-based compensation schemes for its workforce and subsidiary employees.